Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Annovis Bio Inc (NY: ANVS )

6.745 +0.205 (+3.13%)
Streaming Delayed Price Updated: 3:33 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 125,394
Open 6.530
Bid (Size) 6.710 (6)
Ask (Size) 6.750 (3)
Prev. Close 6.540
Today's Range 6.367 - 6.890
52wk Range 4.530 - 22.49
Shares Outstanding 13,797,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Research Suggests Cancer Survivors are Less Prone to Alzheimer’s Development
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission
Via Investor Brand Network

Performance

YTD
-64.37%
-64.37%
1 Month
-31.31%
-31.31%
3 Month
-29.81%
-29.81%
6 Month
-11.83%
-11.83%
1 Year
+2.20%
+2.20%

More News

Read More
Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — Annovis Bio Inc. Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease (‘CTAD’) 2024 Conference
Via Investor Brand Network
Study Explores How Antimicrobials Impact the Risk of Developing Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Details Promising Phase 3 Path for Alzheimer’s Treatment on The BioMedWire Podcast
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Key Alzheimer’s Research at CTAD Conference in Madrid
Via Investor Brand Network
Analysis of Medical Records Repeatedly Links Viruses to Alzheimer’s
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025
Via Investor Brand Network
Exposures Product Safety
Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Addressing Vision Problems Could Lower Risk of Dementia, Study Finds
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Expert Says Alzheimer’s Disease Could Be an Autoimmune Illness
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.